000			03976nam a22004455i 4500
999			_c394449 _d394449
001			394449
003			ES-MaUEC
005			20230102142725.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			221118s2022 sz | s |||| 0|eng d
020			_a9783031113635
024	7		_a10.1007/978-3-031-11363-5 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRA638 _b2022
245	0	0	_aInfectious Complications in Biologic and Targeted Therapies _cedited by Carlos Cervera, Jose Maria Aguado
250			_a1st edition 2022
264		1	_aCham _bSpringer International Publishing _c2022
300			_a1 recurso en línea (X, 473 páginas) _b26 ilustraciones, 19 ilustraciones a color
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_aarchivo de texto _bPDF
505	0		_aOverview on the risk of infection associated with biologic and targeted therapies -- Timeline of infections associated with biologic and targeted therapies -- Infectious disease evaluation of candidates to new therapies -- Vaccines and biologic and targeted therapies -- Travel and risk of infections -- Anti-necrosis tumoral factor-alpha agents -- CD19-targeted agents -- CD20-targeted agents -- CD22-targeted agents -- CD30-targeted agents -- CD33 and CD38-targeted agents -- CD40 and CD319-targeted agents -- CD52-targeted agents -- CCR4-targeted agents -- Cell-surface receptors I: VEFG targeted agents -- Cell-surface receptors II: Epidermal growth factor receptor-targeted agents -- Interleukin-1 targeted agents -- Interleukin-5 and interleukin-6 targeted agents -- Interleukin-12/23 p40 targeted agents -- Sphingosine-1 phosphate receptor modulators -- Immune checkpoint inhibitors -- α4-integrin-targeted agents -- Tyrosin-kinase inhibitors -- Bcl-2, JAK and mTOR inhibitors -- Infections associated with the use of CarT cells -- Pulmonary infiltrates -- Tuberculosis -- Cytomegalovirus and other herpesviruses -- Invasive fungal infections -- Progressive multifocal leukoencephalopathy -- Hepatitis virus.
520			_aThis book aims to approach the epidemiology, diagnosis and management of infectious complications related to the use of biologic and targeted therapies. The first part is a general overview on the epidemiology and prevention of infections with the use of these agents. Timelines, pre-treatment evaluation, use of vaccines and travel counseling. In the second part, we will analyze the specific risk of infections associated with the use of the most important agents. The third part approach the problem on a syndromic point of view. For example, how to evaluate pulmonary infiltrates in a patient receiving biologic agents. This part III includes the most difficult and conflicting syndromes that clinicians may face when evaluating these patients. This book is intended not only for infectious diseases specialists, but also for different medical specialties prescribing biologic and targeted therapies.
988			_aSpringer_Medicine_2022
650		7	_2embne _9138409 _aVacunación _xComplicaciones
650		7	_2embne _9210071 _aEnfermedades infecciosas _xPrevención
650		7	_2embne _9138404 _aEnfermedades infecciosas _xAspectos inmunológicos
700	1		_aCervera, Carlos _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aAguado, Jose Maria _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
776	0	8	_iPrinted edition: _z9783031113628
776	0	8	_iPrinted edition: _z9783031113642
776	0	8	_iPrinted edition: _z9783031113659
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-031-11363-5 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b12/2022 _dz _esc _zSI